Dr. José Trevejo is a physician-scientist and an infectious disease specialist who has spent his career pursuing his passion for leading research and development teams in the advancement of novel therapeutics for serious diseases. Prior to his current role as Chief Development Officer at Rocket Pharma, he was CEO at SmartPharm Therapeutics that is currently developing novel countermeasures for COVID-19. Prior to SmartPharm, Dr. Trevejo served as Vice President, Clinical Development at Cyclerion Therapeutics. Dr. Trevejo joined Ironwood/Cyclerion from Visterra, where he was a member of the Executive Team and lead the pre-clinical and clinical development of novel biologics for infectious diseases. While at Visterra he oversaw the transition to a clinical stage company as well as helped to secure a $215 million DHHS award to support development of a novel treatment for influenza. Prior to Visterra, he held clinical development leadership positions at Genentech and Vertex Pharmaceuticals. Before entering the biotechnology industry, he served as Instructor in Medicine at Harvard Medical School and was a Principal Biomedical Scientist at the Draper Laboratory working on novel diagnostics for tuberculosis and other infectious diseases. Dr. Trevejo completed his clinical training at BWH/BIDMC/Harvard Medical School and earned his M.D. and Ph.D. from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York.